Till Giese

• The modern pharma and med tech supply chain must constantly balance business continuity, cost control and ESG  
• Is it possible to optimise every one of these drivers whilst continuing to ensure the highest possible patient outcomes, or is there always a natural trade off? 
• How is formulating a clear mission and roadmap centred around people, process and digital technologies – with a focus upon automation - central to this balancing act?  
• Focusing on real life examples and use cases - what have been the biggest wins in achieving this balance at major producers? 

(20 max - by invitation only)